Peter A. Gottlieb - Concepedia

Author

Peter A. Gottlieb

Also Known As

Adriana Weinberg, Anna L. Gloyn, Carla J. Greenbaum, Christopher Webb, Gottlieb, Peter A, Lexie Chesshir, Lim, Noha, Lindsey Baden, M. Wenzke, Maria F. Gomez

362

Publications

23.5K

Citations

H-Index

181

Concepts

All Affiliations

University of Colorado Denver University of Colorado Health University of California, San Francisco Benaroya Research Institute University of Florida

About

Peter A. Gottlieb is an author at University of Colorado Denver specializing in medicine, diabetes, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Engineering	7	7	224
2	Health Sciences	4	4	1.3K
3	Education	2	2	85
4	Humanities	1	1	35
5	Language Studies	1	1	35

Peter A. Gottlieb

138

Publications

17.6K

Citations

H-Index

Page 1

	Year	Citations
CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells Weihong Liu, Amy Putnam, Xuyu Zhou, The Journal of Experimental Medicine T-regulatory CellImmune RegulationImmunologyRegulatory T CellsCd4 T Cell Responses	2006	2.6K
Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function Mark D. Pescovitz, Carla J. Greenbaum, Heidi Krause‐Steinrauf, New England Journal of Medicine	2009	1.1K
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes Kevan C. Herold, Brian N. Bundy, S. Alice Long, New England Journal of Medicine	2019	1K
The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes Janet M. Wenzlau, Kirstine Juhl, Liping Yu, Proceedings of the National Academy of Sciences Metabolic SyndromeZinc Transporter Znt8Microarray Expression ProfilingAutoimmune DiseaseMedicine	2007	990
Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial Tihamer Orban, Brian N. Bundy, Dorothy J. Becker, The Lancet Diabetes ManagementDiabetesCo-stimulation ModulationDiabetic NeuropathyPlacebo-controlled Trial	2011	589
Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial Kevan C. Herold, Stephen E. Gitelman, Mario R. Ehlers, Diabetes	2013	396
Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial Diane K. Wherrett, Brian N. Bundy, Dorothy J. Becker, The Lancet VaccinationDiabetes ManagementAutoimmune DiseaseInsulin ManagementDiabetes	2011	364
Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes Manuela Battaglia, Simi Ahmed, Mark S. Anderson, Diabetes Care Metabolic SyndromeDisease HeterogeneityTranslational MedicineType 1Genetic Determinant	2019	331
Fall in C-Peptide During First 2 Years From Diagnosis Carla J. Greenbaum, Craig A. Beam, David Boulware, Diabetes Metabolic SyndromeType 1Diabetes ManagementDiabetes EpidemiologyDiabetes Trialnet Studies	2012	316
Monocytes from Patients with Type 1 Diabetes Spontaneously Secrete Proinflammatory Cytokines Inducing Th17 Cells Elizabeth M. Bradshaw, Khadir Raddassi, Wassim Elyaman, The Journal of Immunology	2009	295

Page 1